139 related articles for article (PubMed ID: 28579210)
1. Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion.
Mihajlović J; Bax P; van Breugel E; Blommestein HM; Hoogendoorn M; Hospes W; Postma MJ
Clin Ther; 2017 Jun; 39(6):1221-1232.e4. PubMed ID: 28579210
[TBL] [Abstract][Full Text] [Related]
2. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.
Stewart DA; Boudreault JS; Maturi B; Boras D; Foley R
Curr Oncol; 2018 Oct; 25(5):300-306. PubMed ID: 30464679
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom.
Rule S; Collins GP; Samanta K
J Med Econ; 2014 Jul; 17(7):459-68. PubMed ID: 24720836
[TBL] [Abstract][Full Text] [Related]
5. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
6. Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma.
Harvey MJ; Zhong Y; Morris E; Beverage JN; Epstein RS; Chawla AJ
PLoS One; 2022; 17(1):e0261336. PubMed ID: 35073335
[TBL] [Abstract][Full Text] [Related]
7. Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
De Cock E; Kritikou P; Sandoval M; Tao S; Wiesner C; Carella AM; Ngoh C; Waterboer T
PLoS One; 2016; 11(6):e0157957. PubMed ID: 27362533
[TBL] [Abstract][Full Text] [Related]
8. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma.
Fargier E; Ranchon F; Huot L; Guerre P; Safar V; Dony A; Hequet N; Bachy E; Savouroux S; Fronteau C; Tomaré P; Tournamille JF; Schwiertz V; Vantard N; Le Gouill S; Gyan E; Salles G; Rioufol C
Ann Hematol; 2018 Jan; 97(1):123-131. PubMed ID: 28993857
[TBL] [Abstract][Full Text] [Related]
9. [Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)].
Favier M; Le Goc-Sager F; Vincent-Cantini I; Launay V; Giroux EA; Lièvremont K; Bonnet I; Barbe C; Duval E; Loric N; Delbaldo C
Bull Cancer; 2018 Oct; 105(10):862-872. PubMed ID: 30244982
[TBL] [Abstract][Full Text] [Related]
10. Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center.
Lee RC; Zou D; Demetrick DJ; Difrancesco LM; Fassbender K; Stewart D
Value Health; 2008; 11(2):221-30. PubMed ID: 18380634
[TBL] [Abstract][Full Text] [Related]
11. Update on the subcutaneous administration of rituximab in Canadian cancer centres.
Stewart D; Aucoin JS; Crosbie T; Forman M; Lye E; Christofides A; Mitha A
Curr Oncol; 2020 Apr; 27(2):113-116. PubMed ID: 32489254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
[TBL] [Abstract][Full Text] [Related]
13. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting.
Schmier J; Ogden K; Nickman N; Halpern MT; Cifaldi M; Ganguli A; Bao Y; Garg V
Clin Ther; 2017 Aug; 39(8):1600-1617. PubMed ID: 28716293
[TBL] [Abstract][Full Text] [Related]
14. Sixty-minute infusion rituximab protocol allows for safe and efficient workflow.
Dotson E; Crawford B; Phillips G; Jones J
Support Care Cancer; 2016 Mar; 24(3):1125-9. PubMed ID: 26268782
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma.
Gota V; Karanam A; Rath S; Yadav A; Tembhare P; Subramanian P; Sengar M; Nair R; Menon H
Cancer Chemother Pharmacol; 2016 Aug; 78(2):353-9. PubMed ID: 27329361
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.
Assouline S; Buccheri V; Delmer A; Gaidano G; Trneny M; Berthillon N; Brewster M; Catalani O; Li S; McIntyre C; Sayyed P; Badoux X
Lancet Haematol; 2016 Mar; 3(3):e128-38. PubMed ID: 26947201
[TBL] [Abstract][Full Text] [Related]
19. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
